BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 11034941)

  • 1. P-selectin expression on platelets determines size and stability of platelet aggregates.
    Merten M; Thiagarajan P
    Circulation; 2000 Oct; 102(16):1931-6. PubMed ID: 11034941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists.
    Michelson AD; Furman MI; Goldschmidt-Clermont P; Mascelli MA; Hendrix C; Coleman L; Hamlington J; Barnard MR; Kickler T; Christie DJ; Kundu S; Bray PF
    Circulation; 2000 Mar; 101(9):1013-8. PubMed ID: 10704169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
    Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
    Naimushin YA; Mazurov AV
    Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K; Schwarz M; Ylänne J; Kohler B; Moser M; Nordt T; Salbach P; Kübler W; Bode C
    Blood; 1998 Nov; 92(9):3240-9. PubMed ID: 9787160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules.
    Naimushin YA; Mazurov AV
    Biochemistry (Mosc); 2003 Feb; 68(2):209-16. PubMed ID: 12693968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
    Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
    Bertram U; Moser M; Peter K; Kuecherer HF; Bekeredjian R; Straub A; Nordt TK; Bode C; Ruef J
    J Thromb Thrombolysis; 2002 Dec; 14(3):197-203. PubMed ID: 12913399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D
    Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of extra- and intracellular calcium chelation on human platelet function and glycoprotein IIb-IIIa complex stability.
    Lanza F; Stierlé A; Gachet C; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1992; 34(1):123-31. PubMed ID: 1523093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
    Caron A; Théorêt JF; Mousa SA; Merhi Y
    J Cardiovasc Pharmacol; 2002 Aug; 40(2):296-306. PubMed ID: 12131559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.